| Name | Title | Contact Details |
|---|
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The companys proprietary drug discovery platform targets mTORC1, which responds to and integrates the cells response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitors therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The companys founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson and Johnson Development Corporation, SR One and The Longevity Fund.
Enzon Pharmaceuticals Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
We are pioneering a better drug discovery process using systems biology to improve the lives of people with neurodegenerative disorders.
ProteoCell Biotechnologies Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Temporary Technical Services Inc is a Jackson, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.